Complete Filing Data
Evommune, Inc. reported Stockholders Equity of $205.57 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Evommune, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Net Income * | -$68.9M | -$66.8M |
| Revenue * | $13.0M | $7.0M |
| Research And Development Expense | $74.0M | $64.2M |
| Other Nonoperating Income Expense | $12.2M | $3.2M |
| Other Nonoperating Expense | $50.0K | $37.0K |
| Operating Income Loss | -$81.1M | -$70.0M |
| Operating Expenses | $94.1M | $77.0M |
| Net Income Loss Available To Common Stockholders Basic | -$68.9M | -$68.3M |
| General And Administrative Expense | $20.0M | $12.8M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q3 2024 |
|---|---|---|
| Net Income * | -$12.5M | -$15.9M |
| Revenue * | $10.0M | |
| Research And Development Expense | $19.6M | $13.3M |
| Other Nonoperating Income Expense | $853.0K | $601.0K |
| Other Nonoperating Expense | $9.0K | $17.0K |
| Operating Income Loss | -$13.3M | -$16.5M |
| Operating Expenses | $23.3M | $16.5M |
| Net Income Loss Available To Common Stockholders Basic | -$12.5M | -$15.9M |
| General And Administrative Expense | $3.7M | $3.2M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Stockholders Equity | $205.6M | -$144.2M | -$77.7M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $45.5M | $16.5M | $29.2M |
| Restricted Cash Noncurrent | $1.4M | $208.0K | |
| Cash And Cash Equivalents At Carrying Value | $44.1M | $16.3M | |
| Temporary Equity Liquidation Preference | $0.00 | $210.3M | |
| Temporary Equity Carrying Amount Attributable To Parent | $0.00 | $191.8M | |
| Short Term Investments | $105.1M | $55.8M | |
| Retained Earnings Accumulated Deficit | -$221.1M | -$152.2M | |
| Property Plant And Equipment Net | $994.0K | $1.3M | |
| Prepaid Expense And Other Assets Current | $4.3M | $1.9M | |
| Other Liabilities Current | $364.0K | $573.0K | |
| Other Assets Noncurrent | $101.0K | $61.0K | |
| Operating Lease Right Of Use Asset | $1.5M | $472.0K | |
| Operating Lease Liability Current | $242.0K | $487.0K | |
| Liabilities Current | $17.9M | $28.0M | |
| Liabilities And Stockholders Equity | $224.9M | $76.1M | |
| Liabilities | $19.4M | $28.5M | |
| Finance Lease Principal Payments | $373.0K | $208.0K | |
| Common Stock Value | $3.0K | $0.00 | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $29.0M | -$12.8M | |
| Assets Current | $153.5M | $74.0M | |
| Assets | $224.9M | $76.1M | |
| Additional Paid In Capital Common Stock | $426.7M | $8.0M | |
| Accrued Liabilities Current | $9.5M | $6.7M | |
| Accretion Amortization Of Discounts And Premiums Investments | $1.8M | $1.8M | |
| Accounts Payable Current | $7.8M | $8.3M | |
| Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 | $10.0K | $1.0M | |
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | $1.8M | ||
| Other Liabilities Noncurrent | |||
| Finance Lease Liability Noncurrent | $181.0K | $535.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|
| Stockholders Equity | -$183.1M | -$171.2M | -$122.5M | -$107.0M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $28.2M | $18.4M | |||
| Restricted Cash Noncurrent | $1.4M | $208.0K | |||
| Cash And Cash Equivalents At Carrying Value | $26.8M | $18.1M | |||
| Temporary Equity Liquidation Preference | $275.6M | ||||
| Temporary Equity Carrying Amount Attributable To Parent | $257.0M | ||||
| Short Term Investments | $49.2M | ||||
| Retained Earnings Accumulated Deficit | -$192.8M | ||||
| Property Plant And Equipment Net | $970.0K | ||||
| Prepaid Expense And Other Assets Current | $5.9M | ||||
| Other Liabilities Current | $371.0K | ||||
| Other Assets Noncurrent | $61.0K | ||||
| Operating Lease Right Of Use Asset | $160.0K | ||||
| Operating Lease Liability Current | $160.0K | ||||
| Liabilities Current | $10.4M | ||||
| Liabilities And Stockholders Equity | $84.5M | ||||
| Liabilities | $10.7M | ||||
| Finance Lease Principal Payments | |||||
| Common Stock Value | $0.00 | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | |||||
| Assets Current | $81.9M | ||||
| Assets | $84.5M | ||||
| Additional Paid In Capital Common Stock | $9.7M | ||||
| Accrued Liabilities Current | $6.3M | ||||
| Accretion Amortization Of Discounts And Premiums Investments | |||||
| Accounts Payable Current | $3.6M | ||||
| Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 | |||||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | |||||
| Other Liabilities Noncurrent | $261.0K | $535.0K | |||
| Finance Lease Liability Noncurrent |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Share Based Compensation | $5.9M | $1.7M |
| Proceeds From Stock Options Exercised | $6.0K | $13.0K |
| Payments To Acquire Property Plant And Equipment | $235.0K | $88.0K |
| Net Cash Provided By Used In Operating Activities | -$76.4M | -$58.2M |
| Net Cash Provided By Used In Investing Activities | -$115.3M | -$4.0M |
| Net Cash Provided By Used In Financing Activities | $220.8M | $49.4M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $2.4M | $1.0M |
| Increase Decrease In Operating Lease Liability | -$730.0K | -$769.0K |
| Increase Decrease In Accrued Liabilities | $2.8M | $2.7M |
| Increase Decrease In Accounts Payable | -$837.0K | $6.5M |
| Proceeds From Issuance Of Convertible Preferred Stock | $65.2M | $49.8M |
| Proceeds From Sale Maturity And Collections Of Investments | $84.1M | $86.4M |
| Proceeds From Issuance Initial Public Offering | $157.3M | |
| Payments To Acquire Investments | $199.2M | $90.3M |
| Increase Decrease In Contract With Customer Liability | -$3.0M |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 6.1M | 1.5M |
| Weighted Average Number Of Diluted Shares Outstanding | 6.1M | 1.5M |
| Earnings Per Share Diluted | $-11.22 | $-45.29 |
| Earnings Per Share Basic | $-11.22 | $-45.29 |
| Temporary Equity Shares Outstanding | 0.00 | 116.7M |
| Temporary Equity Shares Issued | 0.00 | 116.7M |
| Temporary Equity Shares Authorized | 10.0M | 157.7M |
| Temporary Equity Par Or Stated Value Per Share | $0.00 | $0.00 |
| Common Stock Shares Outstanding | 31.5M | 1.6M |
| Common Stock Shares Issued | 31.5M | 1.6M |
| Common Stock Shares Authorized | 500.0M | 223.6M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q3 2024 |
|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 1.5M | 1.5M |
| Weighted Average Number Of Diluted Shares Outstanding | 1.5M | 1.5M |
| Earnings Per Share Diluted | $-8.07 | $-10.47 |
| Earnings Per Share Basic | $-8.07 | $-10.47 |
| Temporary Equity Shares Outstanding | 157.7M | |
| Temporary Equity Shares Issued | 157.7M | |
| Temporary Equity Shares Authorized | 157.7M | |
| Temporary Equity Par Or Stated Value Per Share | $0.00 | |
| Common Stock Shares Outstanding | 1.6M | |
| Common Stock Shares Issued | 1.6M | |
| Common Stock Shares Authorized | 223.6M | |
| Common Stock Par Or Stated Value Per Share | $0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 |
|---|---|---|
| Vesting Of Early Exercised Options Value | $40.0K | $50.0K |
| Investment Income Interest | $3.3M | $3.2M |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $5.9M | $1.7M |
| Vesting Of Early Exercised Sock Options | $40.0K | $50.0K |
| Stock Issued During Period Value Stock Options Exercised | $6.0K | $13.0K |
| Interest Paid Net | $7.0K | $34.0K |
| Depreciation And Amortization | $1.4M | $1.3M |
| Stock Issued During Period Shares Stock Options Exercised | 3.5K | 6.3K |
| Financing Obligation Payments | $158.0K | $215.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q3 2024 |
|---|---|---|
| Vesting Of Early Exercised Options Value | $10.0K | $12.0K |
| Investment Income Interest | $862.0K | $618.0K |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $561.0K | $401.0K |
| Vesting Of Early Exercised Sock Options | ||
| Stock Issued During Period Value Stock Options Exercised | ||
| Interest Paid Net | ||
| Depreciation And Amortization | ||
| Stock Issued During Period Shares Stock Options Exercised | ||
| Financing Obligation Payments |
Most recent annual filing with the SEC: March 5, 2026
Data sourced from SEC EDGAR public filings as of August 8, 2026.